Physician profile
Stanley P Sharp
NPI 1962505081
$4,758.94
in general payments reported to CMS, 2019-2025
34 companies · $511 in 2025
The $511 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $604 · 2020: $775 · 2021: $907 · 2022: $750 · 2023: $492 · 2024: $720 · 2025: $511.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,713 · Education: $10.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,712.52 |
| Education | $10.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $771.41 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Acadia Pharmaceuticals INC | $706.52 | 2020-2025 | Nuplazid |
| Novo Nordisk INC | $583.40 | 2019-2025 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $332.80 | 2019-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $317.14 | 2020-2023 | Belsomra, Steglatro |
| Pfizer INC. | $267.37 | 2019-2024 | |
| Esperion Therapeutics, INC. | $206.31 | 2020-2025 | Nexletol |
| Astrazeneca Pharmaceuticals LP | $183.56 | 2019-2025 | Farxiga, Breztri |
| Janssen Pharmaceuticals, INC | $161.26 | 2019-2022 | |
| Daiichi Sankyo INC. | $150.31 | 2019-2021 | |
| Abbvie INC. | $142.47 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $128.91 | 2023-2025 | Nuedexta |
| Nevro Corp. | $128.55 | 2024 | Senza |
| Medtronic, INC. | $108.44 | 2025 | Pulseselect |
| Novartis Pharmaceuticals Corporation | $93.50 | 2019-2024 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $68.51 | 2019 | |
| Mylan Specialty L.P. | $47.22 | 2019-2021 | |
| Philips North America LLC | $44.14 | 2025 | Coronary Other, Eagle Eye |
| E.R. Squibb & Sons, L.L.C. | $36.14 | 2021 | |
| Eisai INC. | $34.41 | 2020 | |
| Exact Sciences Corporation | $28.63 | 2025 | Cologuard Collection Kit |
| Genentech USA, INC. | $21.77 | 2021 | |
| Electromed, INC. | $20.77 | 2025 | Smartvest |
| Kowa Pharmaceuticals America, INC. | $20.66 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.91 | 2022 | |
| Glaxosmithkline, LLC. | $18.39 | 2024 | Trelegy Ellipta |
| Bausch Health US, LLC | $17.12 | 2021 | |
| Sanofi Pasteur INC. | $15.71 | 2019 | |
| Jazz Pharmaceuticals INC. | $15.08 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.52 | 2021 | |
| Biogen, INC. | $14.32 | 2022 | |
| Shield Therapeutics INC | $13.41 | 2023 | Accrufer |
| Abbott Laboratories | $13.15 | 2022 | |
| Boston Scientific Corporation | $13.13 | 2023 | Watchman Access System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stanley Sharp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.